(Q46177989)

20 December 2017

title

Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression (English)

1 reference

20 December 2017

1 reference

S Collot-Teixeira

1

1 reference

20 December 2017

F De Lorenzo

2

1 reference

20 December 2017

L Waters

3

1 reference

20 December 2017

C Fletcher

4

1 reference

20 December 2017

D Back

5

1 reference

20 December 2017

S Mandalia

6

1 reference

20 December 2017

A Pozniak

7

1 reference

20 December 2017

S Yilmaz

8

1 reference

20 December 2017

J L McGregor

9

1 reference

20 December 2017

B Gazzard

10

1 reference

20 December 2017

M Boffito

11

1 reference

20 December 2017

language of work or name

English

0 references

publication date

31 December 2008

1 reference

20 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

20 December 2017

volume

85

1 reference

20 December 2017

issue

4

1 reference

20 December 2017

page(s)

375-378

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1038/clpt.2008.243

exact match

0 references

cites work

HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Components of the "metabolic syndrome" and incidence of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Metabolic-inflammatory changes, and accelerated atherosclerosis in HIV patients: rationale for preventative measures

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

The nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

CD36 and macrophages in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

CD36 overexpression in ritonavir-treated THP-1 cells is reversed by alpha-tocopherol

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

CD36 deficiency induced by antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Effects of HIV protease inhibitor therapy on lipid metabolism

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Clinical value of C-reactive protein measurements in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.243

7 January 2021

Identifiers

DOI

10.1038/CLPT.2008.243

1 reference

20 December 2017

Dimensions Publication ID

1032174958

0 references

Fatcat ID

release_ysrdte4lbvbvhd2hko273z7ufu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ysrdte4lbvbvhd2hko273z7ufu

24 November 2022

mapped directly with Wikidata item

1 reference

20 December 2017